Printer Friendly

DEPRENYL RESEARCH CO-CHAIRMAN SENDS LETTER TO SHAREHOLDERS

 DEPRENYL RESEARCH CO-CHAIRMAN SENDS LETTER TO SHAREHOLDERS
 TORONTO, Nov. 25, /PRNewswire/ -- Deprenyl Research Limited (NASDAQ: DEPLF; TSE: DEP), an independent Canadian pharmaceutical company, released today the following letter from its Co-Chairman, Morton P. Shulman, M.D., to its shareholders:
 "I wish to restate a number of positive developments concerning your company. The first is that new and repeat prescriptions for ELDEPRYL(R) continue to trend upward. In addition, clinical trials are proceeding well on the use of ELDEPRYL in new indications such as Alzheimer's disease, Multiple Sclerosis and ALS (Lou Gehrig's disease). Development is also progressing nicely on an improved dosage form for ELDEPRYL at the University of Montreal. The company also anticipates approval for the use of ELDEPRYL for early stage Parkinson's disease in the first quarter of 1992, which will increase the market for ELDEPRYL. As a result, your company has achieved a strong and competitive position for its leading drug while at the same time continuing to develop its other products in the fields of neurology, dermatology and osteoporosis.
 "Because of the foregoing strengths and the protection provided by the ELDEPRYL process patent and the time required for regulatory approval in Canada, I believe that our company is in a strong position to handle any potential threat from generic competitors. In the month of November I personally increased my holdings in our company by 142,300 shares to 1,595,168 shares."
 -0- 11/25/91
 /CONTACT: Morton P. Schulman, co-chairman, or James P. Doherty of Deprenyl Research, 416-537-4372, or fax, 416-537-1653; or Irving L. Straus of Straus Corporate Communications, 212-768-2477, or fax, 212-768-2476, for Deprenyl/
 (DEPLF) CO: Deprenyl Research Limited ST: Ontario IN: MTC SU:


KD-JT -- NY045 -- 6831 11/25/91 12:09 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 25, 1991
Words:288
Previous Article:THE R.O.C. TAIWAN FUND REPORTS THIRD QUARTER FINANCIAL HIGHLIGHTS
Next Article:CRA APPROVAL RECEIVED BY MITSUI MANUFACTURERS BANK
Topics:


Related Articles
DEPRENYL RESEARCH COMMENTS ON NEWSPAPER REPORT
DEPRENYL RESEARCH LIMITED REPORTS EARNINGS
DEPRENYL RESEARCH COMMENTS ON STOCK PRICE
DEPRENYL RESEARCH CHAIRMAN ISSUES STATEMENT ON SELL ADVISORY
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL ANNOUNCES AGREEMENT TO ACQUIRE CONTROL OF LIPOPHARM
DEPRENYL RESEARCH ANNOUNCES FINAL PROSPECTUS OF BONE HEALTH INC.
DEPRENYL RESEARCH LIMITED REASSURES SHAREHOLDERS
DEPRENYL RESEARCH LTD. & BONE HEALTH INC. TO AWAIT FULL ANALYSIS OF CLINICAL TRIALS BEFORE ISSUING FINAL AMENDMENTS TO PROSPECTUS
DEPRENYL RESEARCH LIMITED ANNOUNCES RETIREMENT OF DR. MORTON SHULMAN

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters